GleamWall
中文EN

EVMN Evommune, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 2044725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-84.4%
TTM EPS YoY131.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-331.4%
ROA-62.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets9.7%
Debt / equity0.00x
Current ratio8.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$10.00M$0$3.00M$0
R&D expense$24.55M$26.41M$17.32M$20.40M$19.64M$19.64M$14.36M$17.83M
SG&A expense$8.78M$8.48M$6.63M$9.31M$3.69M$3.36M$3.67M$3.62M
Operating income-$33.33M-$34.90M-$23.95M-$29.72M-$13.33M-$22.99M-$15.03M-$21.45M
Income tax$0$0$0$0$0$0$0$0
Net income-$30.88M-$32.25M-$21.67M-$28.27M-$12.47M-$13.56M-$14.56M-$20.73M
EBITDA-$33.13M-$34.70M-$23.85M-$29.62M-$13.23M-$22.79M-$14.83M-$21.88M
EPS (basic)-0.85-0.89-0.64—-8.07-8.80-9.48—
EPS (diluted)-0.85-0.89-0.64—-8.07-8.80-9.48—
Weighted avg. shares (diluted)36.33M36.14M33.67M—1.55M1.54M1.53M—
Balance sheet
Cash & equivalents$47.57M$60.03M$48.32M$44.06M$26.82M$61.84M$5.70M$16.46M
Short-term investments$121.07M$140.76M$163.15M$105.14M$49.24M——$55.78M
Current assets$174.56M$204.25M$215.85M$153.48M$81.94M——$73.99M
PP&E, net$1.63M$1.65M$1.64M$994,000$970,000——$1.33M
Total assets$278.30M$301.95M$322.45M$224.95M$84.54M——$76.06M
Current liabilities$20.48M$17.49M$10.60M$17.91M$10.42M——$27.98M
Total liabilities$26.93M$24.36M$17.90M$19.38M$10.68M——$28.52M
Shareholders' equity$251.37M$277.59M$304.56M$205.57M-$183.14M-$171.23M-$158.24M-$144.24M
Shares outstanding36.38M36.28M36.02M31.52M1.55M——1.55M
Cash flow statement
Operating cash flow-$25.88M-$20.32M-$27.50M-$16.70M-$9.63M-$26.21M-$23.90M-$18.51M
Capital expenditure$233,000$183,000$83,000$104,000$131,000$0$0$0
Free cash flow-$26.11M-$20.50M-$27.59M-$16.80M-$9.77M-$26.21M-$23.90M-$18.51M
Investing cash flow$13.32M$31.29M-$85.36M-$122.90M-$23.91M$18.00M$13.50M-$33.08M
Financing cash flow$94,000$532,000$117.11M$156.85M-$274,000$64.34M-$152,000$49.70M
Depreciation & amortization$200,000$200,000$100,000$100,000$100,000$200,000$200,000-$427,000
Stock-based compensation$4.42M$4.60M$3.45M$4.20M$561,000$557,000$544,000$494,000

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.